Research programme: respiratory syncytial virus vaccines - AmVac

Drug Profile

Research programme: respiratory syncytial virus vaccines - AmVac

Alternative Names: AMV-601; AMV-602; AMV-603; AMV-611; RespiVac

Latest Information Update: 02 Jul 2015

Price : $50

At a glance

  • Originator AmVac
  • Developer AmVac; University of Siena
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parainfluenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 02 Jul 2015 Preclinical trials in Respiratory syncytial virus infections (Prevention) and Parainfluenza virus infections (Prevention) in Switzerland (Intranasal)
  • 22 Apr 2014 Preclinical development of AMV 602 is ongoing
  • 29 Oct 2012 Preclinical development is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top